Molecular and cellular mechanisms of CLL: novel therapeutic approaches. (Q37504699)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

Molecular and cellular mechanisms of CLL: novel therapeutic approaches (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Lisa Pleyer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Richard Greil

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

2 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

405-418

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

The activation and subsequent regulatory roles of Lyn and CD19 after B cell receptor ligation are independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Immunoglobulin gene diversification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Evolution of autoantibody responses via somatic hypermutation outside of germinal centers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Prognostic markers in chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

CD38/CD19: a lipid raft-dependent signaling complex in human B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Elucidating the role of protein kinase C in chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase C II

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Subversion of protein kinase C alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Chronic B cell malignancies and bone marrow microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Microenvironmental interactions and survival of CLL B-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

The levels of TNF alpha, IL4 and IL10 production by T-cells in B-cell chronic lymphocytic leukaemia (B-CLL)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

The immunodeficiency of chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

CD45RO+ T-cells immunoregulate spontaneous in vitro immunoglobulin production by normal and chronic lymphocytic leukaemia B-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

CD154 gene therapy for human B-cell malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

CD38 at the junction between prognostic marker and therapeutic target.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

A chemokine-driven positive feedback loop organizes lymphoid follicles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Lenalidomide--the phoenix rises.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

From the bench to the bedside: emerging new treatments in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Targeting TRAIL agonistic receptors for cancer therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Bcl-2-regulated apoptosis: mechanism and therapeutic potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Tetrocarcin-A--induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Expression and transcriptional regulation of functionally distinct Bmf isoforms in B-chronic lymphocytic leukemia cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

MiR-15a and miR-16-1 cluster functions in human leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

miR-15 and miR-16 induce apoptosis by targeting BCL2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Imatinib sensitizes CLL lymphocytes to chlorambucil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.72

Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia

31 March 2020

1 reference

12 December 2020

Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells

1 reference

12 December 2020

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

1 reference

12 December 2020

Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.

1 reference

12 December 2020

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

1 reference

12 December 2020

CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation

1 reference

12 December 2020

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

12 December 2020

Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.

1 reference

12 December 2020

Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells

1 reference

12 December 2020

Follicular dendritic cells adhere to fibronectin and laminin fibers via their respective receptors.

1 reference

12 December 2020

Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses

1 reference

12 December 2020

T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease

1 reference

12 December 2020

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

1 reference

12 December 2020

T-cell subpopulations in chronic lymphocytic leukemia: abnormalities in distribtuion and in in vitro receptor maturation

1 reference

12 December 2020

Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia

1 reference

12 December 2020

An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia

1 reference

12 December 2020

10.1038/NRCLINONC.2009.72

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19488076%20AND%20SRC:MED&resulttype=core&format=json